Miles Lab

Publications

Fobare, S; Sharpe, C; Quinn, K; Bryant, K; Miles, LA; Bowman, RL; Cheney, C; Furby, C; Long, M; Fyock, K; Perentesis, JP; Eisfeld, A-K; Hertlein, E; Byrd, JC. Characterization of the clonal hierarchy and immunophenotype of PTPN11 mutations in acute myeloid leukemia. JCI Insight. 2026; 11(4).

Miles, LA. Runx2 takes center stage in regulating HSC expansion. Blood. 2025; 146(26):3135-3136.

Schurer, A; Ilyas, H; Maron, M; Hegde, S; Leyden, M; Roy, I; Hyka, R; Dada, L; Shabanowitz, J; Hunt, D; Belizaire, R; Kitamura, S; Gritsman, K; Shechter, D. TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated Acute Myeloid Leukemia. Blood. 2025; 146(Supplement 1):869-869.

Anandappa, A; Trivedi, V; Bones, M; Raval, J; Hefner, R; Wooten, A; Bowman, R; Levine, R; Starczynowski, D; Miles, L. RAS G12 and Q61 codon mutations confer distinct disease characteristics in Acute Myeloid Leukemia and exhibit differential response to RAS(ON) inhibitor RMC-7977. Blood. 2025; 146(Supplement 1):3229-3229.

Krishnan, A; Miles, LA; Challen, GA. Cell-extrinsic factors contribute toward myeloid-biased expansion in Tet2-mutant clonal hematopoiesis. Experimental Hematology. 2025; 148:104816.

Goda, C; Kulkarni, R; Bustos, Y; Li, W; Rudich, A; Balcioglu, O; Chidester, S; Urs, AP; Karunasiri, M; Al-Marrawi, Y; Viny, AD; Miles, LA; Miller, KE; Dorrance, AM. Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia. Leukemia. 2025; 39(1):51-63.

Bowman, RL; Dunbar, AJ; Mishra, T; Xiao, W; Waarts, MR; Maestre, IF; Eisman, SE; Cai, L; Mowla, S; Shah, N; Miles, LA; Ferrell, PB; Trowbridge, JJ; Levine, RL. In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy. Cancer Cell. 2024; 42(11):1955-1969.e7.

Lee, D; Abu-Shihab, Y; Nicolet, D; Mrózek, K; Routbort, M; Patel, KP; Walker, CJ; Buss, J; Stiff, A; Laganson, A; Blachly, JS; Loghavi, S; Eisfeld, A-K; Miles, LA. BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML. Blood. 2024; 144(Supplement 1):2921.

Stiff, A; Fornerod, M; Kain, BN; Nicolet, D; Kelly, BJ; Miller, KE; Mrózek, K; Boateng, I; Bollas, A; Garfinkle, EAR; Salomonis, N; Grimes, HL; Mardis, ER; Eisfeld, A-K. Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nature Genetics. 2024; 56(11):2434-2446.

Waarts, MR; Mowla, S; Boileau, M; Martinez Benitez, AR; Sango, J; Bagish, M; Fernández-Maestre, I; Shan, Y; Eisman, SE; Park, YC; Butler, JM; Cai, SF; Bowman, RL; Levine, RL. CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype-specific Vulnerability in IDH2- and TET2-mutant Cells. Cancer Discovery. 2024; 14(10):1860-1878.

Schwede, M; Jahn, K; Kuipers, J; Miles, LA; Bowman, RL; Robinson, T; Furudate, K; Uryu, H; Tanaka, T; Sasaki, Y; Levine, R; Beerenwinkel, N; Takahashi, K; Majeti, R. Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity. Leukemia. 2024; 38(7):1501-1510.

Abu-Shihab, Y; Nicolet, D; Mrózek, K; Routbort, M; Patel, KP; Walker, CJ; Buss, J; Stiff, A; Laganson, A; Dinardo, CD; Blachly, JS; Miles, LA; Eisfeld, A-K; Loghavi, S. BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML. Blood. 2023; 142(Supplement 1):1575.

Li, J; Malouf, C; Miles, LA; Willis, MB; Pietras, EM; King, KY. Chronic inflammation can transform the fate of normal and mutant hematopoietic stem cells. Experimental Hematology. 2023; 127:8-13.

Robinson, TM; Bowman, RL; Persaud, S; Liu, Y; Neigenfind, R; Gao, Q; Zhang, J; Sun, X; Miles, LA; Cai, SF; Dogan, A; Roshal, M; Levine, RL; Xiao, W. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Science Advances. 2023; 9(38):eadg0488.

Schwede, M; Jahn, K; Miles, LA; Bowman, RL; Kuipers, J; Robinson, TM; Ediriwickrema, A; Gentles, AJ; Levine, R; Beerenwinkel, N; Takahashi, K; Majeti, R. Abstract A49: Characterizing the order of mutation acquisition in acute myeloid leukemia using large-scale single-cell sequencing. Blood Cancer Discovery. 2023; 4(3_Supplement):a49-a49.

Gurska, LM; Okabe, R; Schurer, A; Tong, MM; Soto, M; Choi, D; Ames, K; Glushakow-Smith, S; Montoya, A; Tein, E; Levine, RL; Goel, S; Halmos, B; Gritsman, K. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. Clinical Cancer Research. 2023; 29(5):943-956.

Stahl, M; Derkach, A; Farnoud, N; Bewersdorf, JP; Robinson, T; Famulare, C; Cho, C; Devlin, S; Menghrajani, K; Patel, MA; Papaemmanuil, E; Tallman, MS; Roshal, M; Goldberg, AD. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. American Journal of Hematology. 2023; 98(1):79-89.

Sanmiguel, JM; Eudy, E; Loberg, MA; Miles, LA; Stearns, T; Mistry, JJ; Rauh, MJ; Levine, RL; Trowbridge, JJ. Cell origin-dependent cooperativity of mutant Dnmt3a and Npm1 in clonal hematopoiesis and myeloid malignancy. Blood advances. 2022; 6(12):3666-3677.